

QUARTERLY REPORT













Contents

Vision & Mission	1
Company Information	2
Chairman's Review	3
Condensed Interim Balance Sheet	4
Condensed Interim Profit And Loss Account	6
Condensed Interim Cash Flows Statement	7
Condensed Interim Statement Of Changes In Equity	8
Selected Notes To The Condensed Interim Financial Statements	9
CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS	
Condensed Interim Consolidated Balance Sheet	14
Condensed Interim Consolidated Profit And Loss Account	16
Condensed Interim Consolidated Cash Flow Statement	17
Condensed Interim Consolidated Statement Of Changes In Equity	18
Selected Notes To The Condensed Interim Consolidated Financial Statements	19





Vision

We at Highnoon Laboratories Limited understand the duties of being responsible corporate citizen and stand true to our conviction and promise to work for the betterment and prosperity of our people.

"Highnoon for a Healthier Nation"

Mission

We strive to maintain excellence in our business practices with the objective to benefit the medical community, consumers, stakeholders and employees; and to improve quality of life by providing quality products.



COMPANY INFORMATION

Board of Directors Registered, Head Office & Plant

Mr. Jawaid Tariq Khan 17.5 Kilometer Multan Road, (Chairman) Lahore -53700, Pakistan.

Mr. Tausif Ahmad Khan (5 Lines)

Fax: +92 (42) 7510037

Mr. Anees Ahmad Khan
(Vice Chairman)

Fax: +92 (42) 7510037

E-mail: info@highnoon.com.pk

URL: www.highnoon-labs.com

Mr. Aslam Hafiz (Chief Executive Officer) Legal Advisors

Mr. Ghulam Hussain Khan Mian Muhammad Ashraf

Raja Muhammad Akram & Company

Mrs. Nosheen Riaz Khan Mrs. Zainub Abbas Tax Advisors

Chief Financial Officer Yousuf Islam Associates

Mr. Javed Hussain
Tel: +92 (42) 7511953
Email: javed@highnoon.com.pk
Auditors

KPMG Taseer Hadi & Company,

Company Secretary Chartered Accountants

Mr. Khadim Hussain Mirza
Tel: +92 (42) 7510036 Shares Registrar
Email: khadim@highnoon.com.pk

Bankers Corplink (Pvt) Ltd.
Wings Arcade,
1-K Commercial,

Habib Bank Limited
United Bank Limited
Faysal Bank Limited

T-K Commercial,
Model Town, Lahore.
Ph: +92 (42) 5839182, 5887262

J.S. Bank Limited Fax: +92 (42) 5869637 Allied Bank Limited





CHAIRMAN'S REVIEW

It is my pleasure to present the financial statements of the Company as well as of the group for the guarter ended 31 March 2009 on behalf of the Board of Directors.

The Company generated sales revenue of 495.267 million during the period under review compared to Rs. 467.126 million in the previous quarter. Gross profit and gross profit as a percentage of sales for the period decreased to Rs.170.675 million and 34.46 % as compared to 181.742 million and 38.91 % respectively. The results for the period under review are marred by general slow down in the macro economic conditions of the country that has resulted in high inflation, high borrowing rates and depreciation of the Pak Rupee against all major currencies.

Lack of clarity on the Government's policy especially in relation to the price control continues to be a major threat to the Industry. The absence of clear, transparent policy on drug pricing continues to impact the overall industry direction, also the slow pace at which new registrations are granted remains a concern area for the Industry.

The Company focuses on certain core therapeutic areas in pharmaceuticals, i.e. Gastroenterology, Cardiology and Gynecology and launches products suiting the needs of this segment. During the period the Company launched Cidine (Cinitapride) tablet an original and researched brand of Almirall Prodesfarma, Spain. The Company expects that the product will be a huge success in the national market. Simultaneous with the launch of new products the Company is enhancing and consolidating its sales and marketing initiative to augment its growth objective.

On behalf of the Board, I would like to express my sincere gratitude to the Shareholders, Doctors, Pharmacist, Consumers, Business partners and the Bankers for the continued patronage and business and to the employees and management for their continued, dedicated, untiring efforts and hard work.

For & On behalf of the Board

Jawaid Tariq Khan Chairman

Lahore: 29 April 2009

Quarterly Report 2009



CONDENSED INTERIM BALANCE SHEET

Jn Audited Au	ıdited
---------------	--------

Note 31 March 31 December 2009 2008 (Rupees in thousand)

EQUITY AND LIABILITIES

Share capital		165,277	165,277
Reserves		347,393	332,802
		512,670	498,079
Surplus on revaluation of assets		199,317	200,959
NON CURRENT LIABILITIES			
Long term loan - Secured		50,160	53,743
Liabilities against assets subject to finance lease		40,464	42,729
Long term advances		17,802	17,126
Deferred liabilities		147,222	143,020
		255,648	256,618
CURRENT LIABILITIES			
Trade and other payables		134,037	108,440
Liability for patent & trademark		6,408	6,408
Markup payable on secured loans		14,501	16,063
Short term bank borrowings - secured		326,994	345,067
Current portion of long term liabilities		44,513	44,513
		526,453	520,491
CONTINGENCIES AND COMMITMENTS	5		
		1,494,088	1,476,147

The annexed notes from 1 to 13 form an integral part of these condensed interim financial statements.

ASLAM HAFIZ
CHIEF EXECUTIVE OFFICER

Quarterly Report 2009

Highnoon Laboratories Limited





AS AT 31 MARCH 2009

Un Audited	Audited
31 March	31 December

Note 2009 2008 (Rupees in thousand)

NON CURRENT ASSETS

Property, plant and equipment	6	678,396	683,288
Intangible assets		64,857 743,253	66,492 749,780
Long term investment		10,000	10,000
Long term deposits		1,562	1,562
CURRENT ASSETS			
Stock in trade		444,480	449,901
Trade debts		122,432	140,987
Advances, deposits and prepayments		61,382	25,007
Other receivables	7	51,477	53,587
Income tax - net		41,641	38,145
Cash and bank balances		17,861	7,178
		739,273	714,805
		1,494,088	1,476,147
		1,474,000	1,470,147



CONDENSED INTERIM PROFIT AND LOSS ACCOUNT

for the first quarter ended 31 March 2009 (Un-Audited)

	Note	First Quarter Ended March 31 2009 2006 (Rupees in thousand)	
		(itapoos ii	. triousuru,
Sales - net	8	495,267	467,126
Cost of sales		324,592	285,384
Gross profit		170,675	181,742
Operating expenses			
Administrative and general		35,924	33,195
Distribution, selling and promotional		98,140	94,050
Finance cost		18,663	12,828
Research and development		1,779	3,251
		154,506	143,324
Operating profit		16,169	38,418
Other operating income		2,841	1,063
		19,010	39,481
Other operating charges		1,646	4,432
Profit / Total Comprehensive income before tax		17,364	35,049
Taxation		4,415	6,995
Profit / Total Comprehensive income after tax		12,949	28,054
Earnings per share - (Rupees) - basic and diluted		0.78	1.70
basis and anatod			

The annexed notes from 1 to 13 form an integral part of these condensed interim financial statements.

ASLAM HAFIZ
CHIEF EXECUTIVE OFFICER

ANEES AHMAD KHA DIRECTOR

Quarterly Report 2009

Highnoon Laboratories Limited





CONDENSED INTERIM CASH FLOW STATEMENT for the first quarter ended 31 March 2009 (Un-Audited)

	Note	First Qua	arter Ended
	Note		rch 31
		2009 (Rupees i	2008 n thousand)
Profit before working capital changes	9	60,433	71,477
WORKING CAPITAL CHANGES			
(Increase)/decrease in current assets:			
Stock in trade		5,421	(20,568)
Trade debts		18,556	(39,578)
Advances, deposits and prepayments		(36,374)	(25,505)
Other receivables		2,108	1,089
Increase in current liabilities:			
Trade and other payables		25,616	22,798
		15,327	(61,764)
Cash generated from operations		75,760	9,713
Taxes paid		(12,094)	(9,053)
Gratuity paid		(330)	(672)
Finance cost paid		(17,353)	(9,208)
Long term advances - net		676	789
Net cash generated from / (used in) operating activities		46,659	(8,431)
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment		(8,829)	(16,103)
Intangible assets acquired		(644)	(31,060)
Disposal of property, plant and equipment		4,890	9,161
Net cash used in Investing activities		(4,583)	(38,002)
CASH FLOWS FROM FINANCING ACTIVITIES			
Repayment of finance lease liabilities		(9,719)	(13,874)
Repayment of Long term loan		(3,583)	-
Short term bank borrowings - net		(18,072)	55,397
Dividend paid		(19)	(59)
Net cash (used in) / generated from financing activities		(31,393)	41,464
Net increase / (decrease) in cash and cash equivalents		10,683	(4,969)
Cash and cash equivalents at beginning of the period		7,178	11,857
Cash and cash equivalents at end of the period		17,861	6,888

The annexed notes from 1 to 13 form an integral part of these condensed interim financial statements.

ASLAM HAFIZ
CHIEF EXECUTIVE OFFICER

Highnoon Laboratories Limited

ANEES AHMAD KHAN DIRECTOR

Quarterly Report 2009



CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY

for the first quarter ended 31 March 2009 (Un-Audited)

Revenue Reserves

	Share Capital	General	Unappropriated Profit	Reserve for issuance of bonus shares	Sub Total	Total
			(Rupees in	thousand)		
Balance as at 01 January 2008	150,252	114,000	185,940	-	299,940	450,192
Current year incremental depreciation - net of tax Total comprehensive income for	-	-	1,825	-	1,825	1,825
the period after tax	-	-	28,054 29,879	-	28,054 29,879	28,054 29,879
Final dividend for the year ended 31 December 2007 @ Rs. 1.5 per share	-	-	(22,538)	-	(22,538)	(22,538)
Transfer for issuance of bonus shares @ 10%	-	-	(15,025) (37,563)	15,025 15,025	(22,538)	(22,538)
Balance as at 31 March 2008	150,252	114,000	178,256	15,025	307,281	457,533
Balance as at 01 January 2009	165,277	114,000	218,801	-	332,801	498,078
Current period incremental depreciation - net of tax	-	_	1,643	-	1,643	1,643
Total comprehensive income for the period after tax	-	-	12,949 14,592	-	12,949 14,592	12,949 14,592
Balance as at 31 March 2009	165,277	114,000	233,393		347,393	512,670

The annexed notes from 1 to 13 form an integral part of these condensed interim financial statements.

ASLAM HAFIZ
CHIEF EXECUTIVE OFFICER





SELECTED NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

for the first quarter ended 31 March 2009 (Un-Audited)

1. THE COMPANY AND ITS OPERATIONS

The Company was incorporated as a private limited company in Pakistan in the year 1984 and converted into an unquoted public limited Company in the year, 1985. Its shares are quoted on all stock exchanges in Pakistan since November 1994. The Company is principally engaged in the manufacture, import and marketing of pharmaceutical and allied consumer products. The Registered office of the Company is situated at 17.5 Km, Multan Road. Lahore.

BASIS OF PREPARATION

These financial statements have been prepared in accordance with the requirements of International Accounting Standard No. 34 " Interim Financial Reporting". These are unaudited and are being submitted to the shareholders as required under clause (xx) of the Code of Corporate Governance and section 245 of the Companies Ordinance, 1984.

3. BASIS OF MEASUREMENT

These financial statements have been prepared under the historical cost convention except for revaluation of property, plant and equipment and certain financial assets at fair value and recognition of certain employee's benefits at present value. In these financial statements, except for the cash flow statement all the transactions have been accounted for on accrual basis.

4. ACCOUNTING POLICIES

The accounting policies used are consistent with those used in the audited financial statements of the Company for the year ended 31 December 2008.

5. CONTINGENCIES AND COMMITMENTS

Contingencies

There has been no change in the contingencies as disclosed in the audited financial statements of the Company for the year ended 31 December 2008.

Commitments

Commitments against irrevocable letters of credit include:

	31 March 2009	31 December 2008	
	(Rupees in thousand		
Raw materials	98,088	67,112	
Packing materials	3,327	1,560	
Finished goods	19,189	7,101	





31 March 31 December 2009 2008 (Rupees in thousand)

6 PROPERTY, PLANT AND EQUIPMENT

Owned Assets - Cost of additions		
		20,365
Building on freehold land	-	
Plant and machinery	2,228	103,652
Laboratory equipment	-	6,004
Furniture and fixtures	9	440
Electric and gas appliances	168	1,833
Office equipment	813	16,775
Vehicles	5,662	23,384
Owned Assets - Cost of disposals		
Plant and machinery	-	524
Office equipment	-	340
Vehicles	3,825	20,972
Leased Assets - Cost of additions		
Vehicles	4,583	22,287
Leased Assets - Cost of disposals		
Office equipment	_	20,028
Vehicles	3,501	25,670
- 61116166	0,001	20,010

Additions in freehold assets include transfer of assets costing Rs. 3,501 thousand (2008: Rs. 54,129 thousand) less accumulated depreciation of Rs. 1,234 thousand (2008: Rs. 22,726 thousand) from leasehold assets. Additions in leasehold assets do not include any transfer from freehold assets under sale and leaseback arrangements.

		31 March 2009	31 December 2008
		(Rupees in	thousand)
7.	TRADE DEBTS - Considered good		
	Secured - against letters of credit	6,836	5,572
	Unsecured		
	Due from related parties		
	Subsidiary - Dynalog Services (Private) Limited	77,793	108,818
	Associated - Route - 2 Health (Private) Limited	80	184
		77,873	109,002
	Others	37,723	26,413
		122,432	140,987





First Quarter Ended

March 31

2009 2008
(Rupees in thousand)

8. SALES-net

Manufactured products Local Export

Purchased products - Local Sales Compensation Third Party (toll manufacturing)

Less: Discount Sales tax

480,562	463,098
20,973	11,383
501,535	474,481
25,727	25,619
9,529	-
10,978	8,795
547,769	508,895
52,276	41,482
226	287
52,502	41,769
495,267	467,126

9. CASH FLOWS FROM OPERATING ACTIVITIES

First Quarter Ended

March 31

2009 2008
(Rupees in thousand)

Profit before taxation
Add/(less): Adjustmen

Add/(less): Adjustments for non-cash charges and other items

Depreciation

Gain on sale of property, plant and equipment

Exchange loss

Provision for defined benefit obligation

Finance cost

Amortization of deferred gain

Profit before working capital changes

17,364	35,049
15,128	14,305
2,279	2,260
(1,715)	(97)
-	1,236
8,715	6,406
18,662	12,829
-	(511)
43,069	36,428
60,433	71.477

10. RELATED PARTY TRANSACTIONS

The related parties and associated undertakings comprises subsidiary, associated companies, staff retirement funds, directors. Transactions with related parties and associated undertakings are as follows. Amounts due from and due to related parties are shown under respective notes to the financial statements.





		First Qua	rter Ended	
10 1	10.1 Sales of goods	March 31		
10.1 Sales of goods		2009 (Rupees in	2008 thousand)	
	Subsidiary	96,307	400,605	
	Associate	10,521	8,609	
10.2	Contribution towards employees' benefits			
	Staff provident fund	2,744	2,501	
	Employees' welfare trust	327	343	

11. DIVIDENDS

The Board of Directors of the Company in their meeting held on 31st March 2009 have proposed final cash dividend at the rate of Rs. 2.50 (2007: Rs. 2.50) per share and bonus shares Nil (2007: 10%) for the year ended 31 December 2008, subject to the approval of shareholders in Annual General Meeting. These interim financial statements do not reflect these appropriations.

12. DATE OF AUTHORIZATION OF ISSUE

The Board of Directors of the company authorized the condensed interim financial statements for issuance on 29th April 2009.

13. GENERAL

Provisions in respect of Worker's Welfare Fund, Worker's Profit Participation Fund and Taxation are made on the basis of management's best estimates for the full financial year and these are subject to final adjustment in the annual audited financial statements.

Figures have been rounded off to the nearest thousands of rupees.

ASLAM HAFIZ
CHIEF EXECUTIVE OFFICER



CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

HIGHNOON LABORATORIES LIMITED and its Wholly Owned Subsidiary Company DYNALOG SERVICES (PRIVATE) LIMITED



CONDENSED INTERIM CONSOLIDATED BALANCE SHEET

Un Audited	Audited
------------	---------

Note = 31 March 2009 2008 (Rupees in thousand)

EQUITY AND LIABILITIES

Share capital	165,277	165,277
Reserves	317,048	282,425
	482,325	447,702
Surplus on revaluation of assets	199,317	200,959
NON CURRENT LIABILITIES		
Long term loan - Secured	50,160	53,743
Liabilities against assets subject to finance lease	40,464	42,729
Long term advances	17,802	17,126
Deferred liabilities	147,222	143,020
	255,648	256,618
CURRENT LIABILITIES		
Trade and other payables	140,043	117,937
Liability for patent & trademark	6,408	6,408
Markup payable on secured loans	15,386	19,455
Short term bank borrowings - secured	326,994	435,071
Current portion of long term liabilities	46,894	47,336
	535,725	626,207
CONTINGENCIES AND COMMITMENTS 5		
	1,473,015	1,531,486

The annexed notes from 1 to 13 form an integral part of these condensed interim financial statements.

ASLAM HAFIZ
CHIEF EXECUTIVE OFFICER

Quarterly Report 2009

Highnoon Laboratories Limited and Its Subsidiary Company





AS AT 31 MARCH 2009

Un Audited	Audited
On Addited	Auditeu

Note 31 March 2009 2008 (Rupees in thousand)

NON CURRENT ASSETS

Property, plant and equipment	6	678,396	683,288
Intangible assets		64,857 743,253	66,492 749,780
Long term deposits		1,562	1,562
CURRENT ASSETS			
Stock in trade		467,635	537,849
Trade debts	7	52,478	45,308
Advances, deposits and prepayments		64,697	45,235
Other receivables		58,351	59,641
Income tax - net		48,565	44,094
Cash and bank balances		21,439	29,597
		713,165	761,724
Non current assets held for sale		15,035	18,420
		728,200	780,144
		1,473,015	1,531,486



CONDENSED INTERIM CONSOLIDATED PROFIT AND LOSS ACCOUNT

for the first quarter ended 31 March 2009 (Un-Audited)

	Note -	First Quarter Ended		
	Note -	March 31		
		2009	2008	
		(Rupees in the	ousand)	
Sales - net	8	600,319	542,893	
Cost of sales		397,330	342,924	
Gross profit		202,989	199,969	
Operating expenses				
Administrative and general		40,634	39,715	
Distribution, selling and promotional		106,271	107,422	
Finance cost		20,198	14,547	
Research and development		1,779	3,251	
		168,882	164,935	
Operating profit		34,107	35,034	
Other operating income		4,934	2,388	
		39,041	37,422	
Other operating charges		1,646	4,432	
Profit / Total Comprehensive income before tax		37,395	32,990	
Taxation		4,415	9,354	
Profit / Total Comprehensive income after tax		32,980	23,636	
Earnings per share - (Rupees)				
- basic and diluted		2.00	1.43	

The annexed notes from 1 to 13 form an integral part of these condensed interim financial statements.

ASLAM HAFIZ
CHIEF EXECUTIVE OFFICER

ANEES AHMAD KHAN DIRECTOR

First Quarter Ended

Quarterly Report 2009

Highnoon Laboratories Limited and Its Subsidiary Company





CONDENSED INTERIM CONSOLIDATED CASH FLOW STATEMENT for the first quarter ended 31 March 2009 (Un-Audited)

Note	First Qu	arter Ended
Note	Ma 2009	2008
Profit before working capital changes 9		in thousand)
Profit before working capital changes 9	79,903	72,147
WORKING CAPITAL CHANGES		
(Increase)/decrease in current assets:		
Stock in trade	70,215	(26,813)
Trade debts	(7,171)	8,708
Advances, deposits and prepayments	(19,462)	(23,945)
Other receivables	1,290	(486)
Increase in current liabilities:		
Trade and other payables	22,125	23,163
	66,997	(19,373)
Cash generated from operations	146,900	52,774
Taxes paid	(13,067)	(9,248)
Gratuity paid	(330)	(672)
Finance cost paid	(21,264)	(10,408)
Long term advances - net	676	789
Net cash generated from operating activities	112,915	33,235
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment	(8,829)	(16,798)
Intangible assets acquired	(644)	(31,071
Disposal of assets held for sales	5,480	
Disposal of property, plant and equipment	4,890	9,161
Net cash generated from / (used in) Investing activities	897	(38,708)
CASH FLOWS FROM FINANCING ACTIVITIES		
Repayment of finance lease liabilities	(10,292)	(15,446)
Repayment of Long term loan	(3,583)	-
Short term bank borrowings - net	(108,076)	26,339
Dividend paid	(19)	(59)
Net cash (used in) / generated from financing activities	(121,970)	10,834
Net (decrease)/increase in cash and cash equivalents	(8,158)	5,361
Cash and cash equivalents at beginning of the period	29,597	32,837
Cash and cash equivalents at end of the period	21,439	38,198

The annexed notes from 1 to 13 form an integral part of these condensed interim financial statements.

ASLAM HAFIZ

CHIEF EXECUTIVE OFFICER Highnoon Laboratories Limited and Its Subsidiary Company ANEES AHMAD KHAN DIRECTOR

Quarterly Report 2009

17



CONDENSED INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

for the first quarter ended 31 March 2009 (Un-Audited)

Revenue Reserves

	Capital	General	Unappropriated Profit	Reserve for issuance of bonus shares	Sub Total	Total
			(Rupees in	thousand)		
Balance as at 01 January 2008	150,252	114,000	110,438	-	224,438	374,690
Current year incremental depreciation - net of tax	-	-	1,825	-	1,825	1,825
Total comprehensive income for the period after tax	-		23,636 25,461		23,636	23,636
Final dividend for the year ended 31 December 2007 @ Rs. 1.5 per share	-	-	(22,538)	_	(22,538)	(22,538)
Transfer for issuance of bonus shares @ 10%	-	-	(15,025) (37,563)	15,025 15,025	(22,538)	(22,538)
Balance as at 31 March 2008	150,252	114,000	98,336	15,025	227,361	377,613
Balance as at 01 January 2009	165,277	114,000	168,425	-	282,425	447,702
Current period incremental depreciation - net of tax	-	-	1,643	-	1,643	1,643
Total comprehensive income for the period after tax	-	-	32,980 34,623	-	32,980 34,623	32,980 34,623
Balance as at 31 March 2009	165,277	114,000	203,048		317,048	482,325

The annexed notes from 1 to 13 form an integral part of these condensed interim financial statements.

ASLAM HAFIZ
CHIEF EXECUTIVE OFFICER

ANEES AHMAD KHAN DIRECTOR

Quarterly Report 2009

Highnoon Laboratories Limited and Its Subsidiary Company





SELECTED NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

for the first quarter ended 31 March 2009 (Un-Audited)

1. COMPANY AND ITS OPERATIONS

1.1 The Highnoon Group comprises of Holding Company Highnoon Laboratories Limited ("HNL") and a wholly owned Subsidiary company Dynalog Services (Private) Limited ("DSL").

HNL was incorporated as a private limited company in Pakistan in the year 1984 under the Companies Ordinance, 1984 and converted into an unquoted public limited company in the year 1985. Its shares are quoted on all stock exchanges in Pakistan since November 1994. HNL is principally engaged in the manufacture, import and marketing of pharmaceutical and allied consumer products. The registered office of HNL is situated at 17.5 Km, Multan Road, Lahore.

DSL was incorporated as a private limited company in Pakistan on 27 April 2004 under the Companies Ordinance,1984 and made a wholly owned subsidiary Company of HNL in September 2004. DSL is principally engaged in the business of trading and distribution of pharmaceutical and other products. The registered office of DSL is situated at 31-Saint John's Park, Lahore.

1.2 The management of the subsidiary has decided to discontinue the subsidiary's operations and accordingly financial statements of subsidiary company have been prepared on nongoing concern basis and the related assets and liabilities approximate to their realizable values.

BASIS OF PREPARATION

These financial statements have been prepared in accordance with the requirements of International Accounting Standard No. 34 " Interim Financial Reporting". These are unaudited and are being submitted to the shareholders as required under clause (xx) of the Code of Corporate Governance an section 245 of the Companies Ordinance, 1984.

3. BASIS OF MEASUREMENT

These financial statements have been prepared under the historical cost convention except for revaluation of property, plant and equipment and certain financial assets at fair value and recognition of certain employee's benefits at present value. In these financial statements, except for the cash flow statement all the transactions have been accounted for on accrual basis.

4. ACCOUNTING POLICIES

The accounting policies used are consistent with those used in the audited financial statements of the Group for the year ended 31 December 2008.





5. CONTINGENCIES AND COMMITMENTS

Contingencies

There has been no change in the contingencies as disclosed in the audited financial statements of the Group for the year ended 31 December 2008.

Commitments

Commitments against irrevocable letters of credit include:

	Note -	31 March 2009	31 December 2008
	Note -	(Rupees in thousand)	
Raw materials		98,088	67,112
Packing materials		3,327	1,560
Finished goods		19,189	7,101

6. PROPERTY, PLANT AND EQUIPMENT

0 1 1 1 0 1 1 1 1		
Owned Assets - Cost of additions		
Building on freehold land	-	20,365
Plant and machinery	2,228	103,652
Laboratory equipment	-	6,004
Furniture and fixtures	9	573
Electric and gas appliances	168	1,833
Office equipment	813	18,298
Vehicles	5,662	25,375
Owned Assets - Cost of disposals		
Plant and machinery	-	524
Office equipment	-	340
Vehicles	3,174	23,384
Leased Assets - Cost of additions		
Vehicles	4,583	24,097
Leased Assets - Cost of disposals		
Office equipment	-	20,605
Vehicles	3,501	33,524
*0.110.00	0,001	30,021

Additions in freehold assets include transfer of assets costing Rs. 3,501 thousand (2008: Rs. 54,129 thousand) less accumulated depreciation of Rs. 1,234 thousand (2008: Rs. 22,726 thousand) from leasehold assets. Additions in leasehold assets do not include any transfer from freehold assets under sale and leaseback arrangements.

7. TRADE DEBTS - Considered good

Secured - against letters of credit	6,836	5,572
Unsecured		
Due from Associate - Route 2 Health (Private) Limited	80	184
Others	45,562	39,552
	52,478	45,308

Quarterly Report 2009

Highnoon Laboratories Limited and Its Subsidiary Company





Note	First Quarter Ended	
	March 31	
	2009	2008
	(Rupees in thousand)	

8. SALES - net

Manufactured products Local Export

Purchased products - Local Sales Compensation Third Party (toll manufacturing)

Less: Discount Sales tax

521,886	469,834
20,973	11,383
542,859	481,217
83,888	78,094
9,529	-
10,978	8,795
647,254	568,106
46,443	24,340
492	873
46,935	25,213
600,319	542,893

9. CASH FLOWS FROM OPERATING ACTIVITIES

Note First Quarter Ended
March 31
2009 2008
(Rupees in thousand)

Profit before taxation 37,395 32,990 Add/(less): Adjustments for non-cash charges and other items Depreciation 15,128 15,295 Amortization of intangible assets 2,279 2,279 Gain on sale of property, plant and equipment (1,717)(97) Gain on sale of assets held for sales (2,095)Exchange loss 1,236 Provision for defined benefit obligation 8,715 6,406 Finance cost 20,198 14,547 Deterioration in pallets 2 Amortization of deferred gain (511) 42,508 39,157 Profit before working capital changes 79,903 72,147

10. RELATED PARTY TRANSACTIONS

The related parties and associated undertakings comprises subsidiary, associated companies, staff retirement funds, directors. Transactions with related parties and associated undertakings are as follows. Amounts due from and due to related parties are shown under respective notes to the financial statements.



Note First Quarter Ended
March 31
2009 2008
(Rupees in thousand)

10.1 Sales of goods Associate

10,521

8,609

10.2 Contribution towards employees' benefits

Staff provident fund Employees' welfare trust 2,827 327 2,860 343

11. DIVIDENDS

The Board of Directors of the HNL in their meeting held on 31st March 2009 have proposed final cash dividend at the rate of Rs. 2.50 (2007: Rs. 2.50) per share and bonus shares Nil (2007: 10%) for the year ended 31 December 2008, subject to the approval of shareholders in Annual General Meeting. These interim financial statements do not reflect these appropriations.

12. DATE OF AUTHORIZATION OF ISSUE

The Board of Directors of the HNL authorized the condensed interim financial statements for issuance on 29th April 2009.

13. GENERAL

Provisions in respect of Worker's Welfare Fund, Worker's Profit Participation Fund and Taxation are made on the basis of management's best estimates for the full financial year and these are subject to final adjustment in the annual audited financial statements.

Figures have been rounded off to the nearest thousands of rupees.

ASLAM HAFIZ
CHIEF EXECUTIVE OFFICER